The Latest Cardiac and Vascular News
Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece PARIS and NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth […]
Quantum Genomics to receive up to $18.5 million in upfront and milestone payments plus double-digit royalties on sales DongWha Pharm to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in South Korea PARIS, Dec. 02, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical […]
PARIS and NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the end of its financing agreement with Negma Group […]
Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales Qilu Pharmaceutical to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greater China region, including Hong Kong and Macao PARIS and NEW […]
PARIS and NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the enrollment of the first patient in the Company’s […]
PARIS and NEW YORK, April 07, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, has released an update on how the current COVID-19 […]
Despite the current public health crisis and any financial consequences it may have, the fact that Quantum Genomics has secured new financing confirms that investors remain confident in its outlook. This round of financing, which includes a loan not to exceed €8 million and the issue of share subscription warrants, was […]
Biolab Sanus Pharmaceutical to receive an exclusive license to develop and commercialize firibastat for the treatment of arterial hypertension in Latin America PARIS and NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the […]
Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension Heart failure: the first patients were enrolled in June in QUORUM, a Phase IIb study of firibastat in heart failure PARIS and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX […]
PARIS and NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that a directly targets the brain to treat resistant hypertension and heart failure, today announced that it is launching an additional study with […]
